Entera Bio Ltd. Market Cap

Market Cap of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Market Cap growth rates and interactive chart. Calculated as stock price times number of shares outstanding.


Highlights and Quick Summary

Current Market Cap of Entera Bio Ltd. is $26 Million (as of December 30, 2019)
  • Market Cap for the quarter ending June 29, 2020 was $33.6 Million (a -9.68% decrease compared to previous quarter)
  • Year-over-year quarterly Market Cap increased by 11.86%
  • Annual Market Cap for 2019 was $26 Million (a -45.68% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Market Cap of Entera Bio Ltd.

Most recent Market Capof ENTX including historical data for past 10 years.

Interactive Chart of Market Cap of Entera Bio Ltd.

Entera Bio Ltd. Market Cap for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $33.55 $37.14
2019 $25.99 $29.99 $39.81 $25.99
2018 $47.86 $47.86

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.